- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03038516
'Palliative-D' Vitamin D to Palliative Cancer Patients (Palliative-D)
'Palliative-D' Vitamin D Supplementation to Palliative Cancer Patients - A Double Blind, Randomised Controlled Trial
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
PROTOCOL IDENTITY AND OBJECTIVES: EudraCT Number 2017-000268-14 Protocol Title: Vitamin D supplementation to palliative cancer patients - A double blind, randomised controlled trial. Acronym: "Palliative-D" Trial Objectives: To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients can decrease opioid consumption, fatigue and infectious burden and increase quality of life.
INVESTIGATIONAL MEDICINAL PRODUCTS (IMP): Test ProductDetremin, MA holder Renapharma; Pharmaceutical Form: Oil Route of Administration: Oral route
METHODOLOGY Trial Design: Double-blind, parallel randomised and placebo controlled trial Dose/Duration 4000 IU/day for 12 weeks
Primary Endpoint:
The decline of opioid-consumption during 12 weeks in the vitamin D group compared to the placebo group, based on 3 measurements with 4 weeks intervals.
Secondary end Points:
- Decline in antibiotic consumption
- Improvement in quality of life
- Improvement in fatigue
- Vitamin D levels in serum after 12 weeks
- Association between opioid dose and genetic polymorphism in genes involved in the effect and metabolism of vitamin D in the body.
Efficacy Parameters:
Opioid dose, translated to fentanyl per hour measured at baseline and at week 4,8 and 12.
Antibiotic consumption expressed as % of days with antibiotics during the last 4 weeks measured at baseline and at week 4, 8 and 12.
Quality of Life measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks. Fatigue measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks. 25-hydroxyvitamin D levels in blood at baseline and after 12 weeks. ESAS (Edmonton Symptom Assessment Scale ) measured at baseline and at week 4, 8 and 12.
Safety Parameters: S-calcium will be controlled in all subjects at baseline, at week 4, 8 and 12 and U-calcium in selected cases Power: The least clinically meaningful effect is estimated to be a 20% decline in opioid dose compared to the placebo. To obtain this result with 80% power the number of patients is estimated to be 127 in each arm i.e. 254 patients in total. This includes a drop-out of 25% per group.
Statistical Analyse plan: The primary endpoint will be analysed using linear regression, using bias corrected and accelerated bootstrap confidence intervals, while controlling for baseline measure of opioid dose (similar to ANCOVA). Adjustment for other background variables - such as vitamin D-level at baseline, gender and age - will be made in a secondary analysis to gain efficiency. The continuous secondary endpoints will be analysed using the same method as the primary endpoint .
POPULATION OF TRIAL SUBJECTS Number of Subjects: 254 (127 vitamin D and 127 placebo) Description of Trial Subjects: Palliative Cancer Patients (any cancer form) with a life expectancy of more than 3 months.
TRIAL TIMETABLE First Subject In Aug 2017 Last Subject In Sept 2019 (25 months to include participants) Last Subject Out Dec 2019 End of intervention Dec 2019 End of follow up Dec2019 End of Trial: Dec 2020
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Stockholm, Schweden, 11219
- Stockholms Sjukhem ASIH
-
Älvsjö, Schweden, 12559
- ASIH Stockholm Södra
-
-
Stockholm
-
Solna, Stockholm, Schweden, 171 54
- ASIH Stockholm Norr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients admitted to ASIH Stockholm Södra or Stockholms Sjukhem.
- Incurable cancer patients with any type of cancer. They could have ongoing oncological treatment but only with palliative intention. No patients with ongoing oncological treatment with curative intended treated will be included.
- The life expectancy should be at least 3 months according to the clinical assessment of the study physician at the screening visit.
- The patient should have no cognitive failure, being able to comprehend oral and written information about the study.
- 25 OHD < 50 nmol/L.
- Men and women aged ≥18
- Signed 'informed consent'
Exclusion Criteria:
- Ongoing vitamin D supplementation at the time for inclusion.
- Serum level of 25-OH vitamin D3 >50 nmol/L
- Known sarkoidosis
- Treatment with tiazides or digoxin or digitoxin
- Primary hyperparathyroidism
- Hypercalcaemia (verified by a laboratory result younger than 2 month)
- Plans to leave the Stockholm county within 12 weeks of inclusion
- History of kidney stones
- Taking part of another clinical study involving drugs
- Hypersensitivity to cholecalciferol and/or any of the excipients
- Other criteria that could jeopardize the study or its intention as judged by the investigator
- Not being able to perform EORTC-QLQ-C15-PAL or ESAS
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Vitamin D
Cholecalciferol (Detremin) solved in MIGLYOL® 812
|
To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
Andere Namen:
|
Placebo-Komparator: Placebo
MIGLYOL® 812
|
To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in opioid dose during 12 weeks
Zeitfenster: 12 weeks
|
The change in decline of opioid-consumption during 12 weeks in the vitamin D group compared to the placebo group, based on 4 measurements with 4 weeks intervals.
|
12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in Antibiotic Consumption during 12 weeks
Zeitfenster: 12weeks
|
Change in Antibiotic consumption expressed as % of days with antibiotics during the last 4 weeks measured at baseline and at week 4, 8 and 12.
|
12weeks
|
Change in Quality of life after 12 weeks
Zeitfenster: 12 weeks
|
Change in Quality of Life measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks.
|
12 weeks
|
Change in Fatigue after12 weeks
Zeitfenster: 12 weeks
|
Change in Fatigue measured with EORTC-QLQ-C15-PAL at baseline and after 12 weeks.
|
12 weeks
|
Change in 25-hydroxyvitamin D levels after 12 weeks
Zeitfenster: 12 weeks
|
Change in 25-hydroxyvitamin D levels in blood at baseline and after 12 weeks.
|
12 weeks
|
Change in Symptom burden during 12 weeks
Zeitfenster: 12 weeks
|
Change in Symptom burden measured with ESAS (Edmonton Symptom Assessment Scale) at baseline and at week 4, 8 and 12.
|
12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Linda Björkhem-Bergman, Assoc Prof, Stockholm Läns Landsting
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- Palliative-D
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Mangel an Vitamin D
-
University of UlsterNorthern Ireland Executive; HSC Public Health AgencyAbgeschlossenVitamin-D-Status | Vitamin-D-KonzentrationVereinigtes Königreich
-
Hospices Civils de LyonAbgeschlossen
-
Horopito LimitedAtlantia Food Clinical TrialsAbgeschlossen
-
Federal University of Rio Grande do SulAbgeschlossen
-
Factors Group of Nutritional Companies Inc.Abgeschlossen
-
Mike O'Callaghan Military HospitalZurückgezogenVitamin-DVereinigte Staaten
-
Rajavithi HospitalQueen Sirikit National Institute of Child HealthAbgeschlossen
-
Universidade de Passo FundoUnbekanntMangel, Vitamin DBrasilien
-
King's College LondonVitamax Wholesalers LLPRekrutierungVitamin-D-ErgänzungVereinigtes Königreich
-
Nutrition Institute, SloveniaNational Institute of Public Health, Slovenia; Slovenian Research Agency; Higher...Anmeldung auf EinladungVitamin-D-SerumspiegelSlowenien
Klinische Studien zur Cholecalciferol
-
Centre of Postgraduate Medical EducationUnbekanntSäugling, Frühchen, KrankheitenPolen
-
Medical University of South CarolinaBeendetMangel an Vitamin D | ErnährungsmangelVereinigte Staaten
-
Johns Hopkins UniversityNational Institute on Aging (NIA)BeendetMangel an Vitamin D | StürzeVereinigte Staaten
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAbgeschlossen
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverAbgeschlossenEntzündungVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexAbgeschlossenNierentransplantationskandidat für die rechte NiereFrankreich
-
University Hospital, AngersMylan LaboratoriesAbgeschlossen
-
University Hospital, MontpellierRekrutierung
-
International Centre for Diarrhoeal Disease Research...Karolinska Institutet; University of Iceland; National Institute of Diseases of...Abgeschlossen
-
Organon and CoAbgeschlossen